Sorafenib for the management of advanced renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 11, Issue 6, 2011, Pages 825-836

  Escudier, Bernard ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

kidney cancer; renal cell carcinoma; sorafenib; tyrosine kinase inhibitor

Indexed keywords

ALPHA INTERFERON; AMG 386; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CARBAMAZEPINE; DEXAMETHASONE; EVEROLIMUS; INTERFERON; PHENYTOIN; PLACEBO; RIFABUTIN; RIFAMPICIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; COLON CANCER; COMORBIDITY; DESQUAMATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; MAXIMUM PLASMA CONCENTRATION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; RASH; RISK FACTOR; SIDE EFFECT; SYSTEMIC THERAPY; VOMITING; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 79959799116     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.55     Document Type: Article

References (64)

1. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34(3), 193-205 (2008
2. Calabró F, Sternberg CN. Novel targeted therapy for advanced renal carcinoma: trials in progress. Curr Opin. Urol. 20(5), 382-387 (2010
3. Escudier B, Kataja V; on behalf of the ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v137-v139 (2010
4. Novara G, Ficarra V, Antonelli A et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur. Urol. 58(4), 588-595 (2010
5. Escudier B. Chemo-immunotherapy in RCC: the end of a story. Lancet 375(9715), 613-614 (2010
6. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999 (Pubitemid 29368255)
7. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5(10), 835-844 (2006 (Pubitemid 44480537)
8. Santoro M, Melillo RM, Carlomagno F, Fusco A, Vecchio G. Molecular mechanisms of RET activation in human cancer. Ann. NY Acad. Sci. 963, 116-121 (2002 (Pubitemid 34721703)
9. McCormick, F. Success and failure on the ras pathway. Cancer Biol. Ther. 6(10), 1654-1659 (2007 (Pubitemid 351590340)
10. Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7(10), 3129-3140 (2008
11. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006 (Pubitemid 46094197)
12. Chang YS, Adnane J, Trail PA et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother. Pharmacol. 59(5), 561-574 (2007 (Pubitemid 46295136)
13. Auclair D, Miller D, Yatsula V et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia 21(3), 439-445 (2007
14. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors? J. Clin. Oncol. 23(5), 965-972 (2005 (Pubitemid 46202316)
15. Flaherty KT, Lathia C, Frye RF, Schuchter L et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a Phase I/II pharmacokinetic interaction study. Cancer Chemother. Pharmacol. (2011) (In Press
16. Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack ofeffect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother. Pharmacol. 57, 685-692 (2006
17. Mross K, Steinbild S, Baas F et al. Results from an in vitro and a clinical/ pharmacological Phase I study with the combination irinotecan and sorafenib. Eur. J. Cancer. 43(1), 55-63 (2007 (Pubitemid 46054474)
18. Strumberg D, Clark JW, Awada A et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four Phase I trials in patients with advanced refractory solid tumors. Oncologist 12(4), 426-437 (2007 (Pubitemid 46698720)
19. Stadler W. The randomized discontinuation trial: a Phase II design to assess growth-inhibitory agents. Mol. Cancer Ther. 6(4), 1180-1185 (2007 (Pubitemid 46711981)
20. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 2505-2512 (2006 (Pubitemid 46630627)
21. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009
22. Hutson TE et al. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from Phase III TARGET. Eur. J. Cancer 46(13), 2432-2440 (2010
23. Beck J, Procopio G, Bajetta et al. Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann. Oncol. (2011) (In Press
24. Stadler WM, Figlin R, McDermott D et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116(5), 1272-1280 (2010
25. Escudier B, Szczylik C, Hutson TE et al. Randomized Phase II trial of first-line treatment with sorafenib versus interferon a-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27(8), 1280-1289 (2009
26. Rini BI, Szczylik C, Tannir NM et al. AMG 386 in combination with sorafenib in patients with metastatic renal cell cancer (mRCC): a randomized, double-blind, placebo-controlled, Phase II study. Presented at: ASCO. Orlando, FL, USA, 17-19 February 2011 (Abstract 70443
27. Vickers MM, Choueriri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 76(2), 430-434 (2010
28. Sablin MP, Negrier S, Ravaud A et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182(1), 29-34 (2009).
29. Rixe O, Bukowski RM, Michaelson MD et al. Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a Phase II study. Lancet Oncol. 8(11), 975-984 (2007 (Pubitemid 47629888)
30. Hutson TE, Bukowski RM, Cowey CL et al. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011
31. Choueiri TK, Duh MS, Clement J et al. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 105(9), 1247-1254 (2010
32. Porta C, Procopio G, Carteni G et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. DOI: 10.1111/j.1464-410X.2011.10186.x (2011) (Epub ahead of print
33. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1), 61-67 (2009
34. Rini BI, Wilding G, Hudes G et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol. 27, 4462-4468 (2009
35. Motzer RJ, Escudier B, Oudard S et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008
36. Escudier B, Lassau N, Angevin E et al. Phase I trial of sorafenib in combination with IFN a-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin. Cancer Res. 13(6), 1801-1809 (2007 (Pubitemid 46952949)
37. Gollob JA, Rathmell WK, Richmond TM et al. Phase II trial of sorafenib plus interferon a-2b as first or second-line therapy in patients with metastatic renal cell cancer. J. Clin. Oncol. 25, 3288-3295 (2007 (Pubitemid 47325614)
38. Ryan CW, Goldman BH, Lara Jr PN et al. Sorafenib with interferon a-2b as first line treatment of advanced renal carcinoma: a Phase II study of the southwest oncology group. J. Clin. Oncol. 3296-3301 (2007 (Pubitemid 47325615)
39. Sosman JA, Flaherty KT, Atkins DF et al. Updated results of Phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer. Presented at: ASCO. Orlando, FL, USA, 25-27 January 2008 (Abstract 5011
40. Jonasch E. Upfront, randomized, Phase 2 trial of sorafenib versus sorafenib and low-dose interferon a in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1), 57-65 (2010
41. Bracarda S, Porta C, Boni C et al. Randomized prospective Phase II trial of two schedules of sorafenib daily and interferon in metastatic renal cell carcinoma. Presented at: ASCO. Orlando, FL, USA, 25-27 January 2008 (Abstract 357
42. Procopio G, Verzoni E, Bracarda S et al. A randomized, prospective, Phase 2 study, with sorafenib and interleukin-2 versus sorafenib alone as first line treatment in advanced renal cell cancer: ROSORC trial. Presented at: ECCO-ESMO. Berlin, Germany, 20-24 September 2009 (Abstraxt O-7107
43. Hongyun L, Zhihong C, Xiangqing Y et al. Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma: preliminary results. Presented at: ASCO. Orlando, FL, USA, 29 May-2 June 2009 (Abstract e16093
44. Tawaga ST, Milowsky MI, Jeske S et al. A Phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium trial NCI 6981. Am. J. Clin. Oncol. (2010) (Epub ahead of print
45. Cen P, Daleiden A, Doshi G, Amato R. A Phase I study of everolimus plus sorafenib in patients with metastatic renal cell carcinoma (mRCCPresented at: ASCO. Orlando, FL, USA, 29 May-2 June 2009 (Abstract e16056
46. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatmentwith temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 7, 24-27 (2009
47. Hong D, Gordon M, Appleman L et al. Interim results from a phase 1b study of safety, pharmacokinetics, and tumor response of the angiopoietin1/2- neutralizing peptibody AMG 386 in combination with AMG 706 (motesanib), bevacizumab or sorafenib in advanced solid tumors. Presented at: ESMO. Stockholm, Sweden, 12-16 September 2008 (Abstract P462
48. Eisen T, Oudard S, Szczylik C et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J. Natl. Cancer Inst. 100(20), 1454-1463 (2008
49. Porta C, Bracarda S, Beck J et al. Efficacy and safety of sorafenib in elderly patients: results from a large open-label, non-comparative Phase III study in European patients with advanced RCC (EU-ARCCSAnn. Oncol. 19(Suppl. 8), viii193, 596P (2008
50. Bukowski RM, Stadler WM, McDermott DF et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 78(5-6), 340-347 (2010
51. Procopio G, Bellmunt J, Dutcher JP et al. Sorafenib in older patients with advanced renal cell carcinoma: subanalysis by age of an integrated database of 8 company-sponsored clinical trials. Presented at: ESMO. Milan, Italy, 8-12 October 2010 (Abstract 906P
52. Eisen T, Beck J, Procopio G et al. Large open label, non-comparative Phase III study of sorafenib in European patients with advanced RCC (EU-ARCCS) - subgroup analysis of patients with and without baseline clinical cardiovascular disease. Ann. Oncol. 19(Suppl. 8), viii194-viii195, 602P (2008
53. Clark JW, Eder JP, Ryan D et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin. Cancer Res. 11(15), 5472-5480 (2005 (Pubitemid 41060823)
54. Moore M, Hirte HW, Siu L et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann. Oncol. 16(10), 1688-1694 (2005). (Pubitemid 41510145)
55. Miller AA, Murry DJ, Owzar K et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J. Clin. Oncol. 27(11), 1800-1805 (2009
56. Khan G, Golshayan A, Elson P et al. Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency. Ann. Oncol. 21(8), 1618-1622 (2010
57. Parsa V, Heilbrun L, Smith D, Sethi A, Vaishampayan U. Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin. Genitourin. Cancer 7(2), E10-E15 (2009
58. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007 (Pubitemid 46089673)
59. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 21(5), 1027-1031 (2009
60. Pena C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin. Can. Res. 16(19), 4853-4863 (2010
61. Gore M, Beck J, Knox J et al. Sorafenib safety profile in >4600 patients with renal cell carcinoma: assessment at 3 month intervals using an integrated database of 8 company sponsored studies. Presented at: ASCO. Chicago, IL, USA, 4-8 June 2010 (Abstract 4605
62. Bokemeyer C, Eisen T, Szczylik C et al. Sorafenib dosage patterns in ≥4600 patients with renal cell carcinoma, including the elderly and patients treated for =12 months: results from an integrated database of 8 company-sponsored trials. Presented at: ESMO. Milan, Italy, 8-12 October 2010 (Abstract 916P
63. Eisen T, Hutson TE, Gore M et al. Sorafenib safety over time in >4600 patients with renal cell carcinoma (RCC): insights from an integrated database of 8 company-sponsored trials. Presented at: ESMO. Milan, Italy, 8-12 October 2010 (Abstract 905P
64. Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit. Rev. Oncol. Hematol. 78(1), 24-32 (2010).